1. ¹Department of Urology, Yonsei University Health System, Seoul, Korea
2. ²Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea
3. ³Department of Urology, College of Medicine, Eulji University, Daejeon, Korea
4. ⁴Department of Urology, College of Medicine, Hallym University, Chuncheon, Korea

Correspondence: Dr CY Oh, Department of Urology, Hallym Univesity College of Medicine, 896, Pyeongchon-dong, Dongan-gu, Anyang-si, Gyeonggi-do 431-070, Korea. E-mail: cyoh@hallym.or.kr

Received 18 November 2008; Revised 31 December 2008; Accepted 9 January 2009; Published online 5 February 2009.

Abstract

We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable -blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3–11.5, IIEF-5 11.95–18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an -blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.